HIGHBuilt-inProduct / Revenue mix
ASSURE WCD
“10-K Item 1A: 'revenues from our ASSURE WCD and associated products and services delivered as part of our Cardiac Recovery System platform will continue to account for nearly all of our revenue'”
KMTS · Concentration risk · 10-K extracted
Kestra Medical Technologies, Lt (KMTS) concentration risks
Updated
The most significant concentration Kestra Medical Technologies, Lt discloses is ASSURE WCD, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Source: Kestra Medical Technologies, Lt’s SEC Form 10-K filed — view the filing on SEC EDGAR ↗
At a glance
Disclosed-size breakdown · 2 disclosed concentrations
HIGH2
MEDIUM0
LOW0
Disclosed concentrations
Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).
HIGHOutside partyCustomer
third-party payors
“10-K Item 1A: 'We derive nearly all our revenue from the direct billing of various third-party payors, including Medicare, Medicaid, private payors and other healthcare-related organizations'”
TrendMatrix Research · concentration synthesis
What these concentrations mean together
updated 2026-10-11Kestra's disclosed concentrations are both product-level and payor-level, and they compound each other. The filing states that revenues from the ASSURE WCD and associated products and services, delivered as part of the Cardiac Recovery System platform, will continue to account for nearly all of the company's revenue. This is a structural single-product exposure: there is no second franchise to absorb a clinical, regulatory, or competitive setback. On the demand side, the company derives nearly all of its revenue from direct billing of third-party payors, including Medicare, Medicaid, private payors and other healthcare-related organizations. This is a dependency on reimbursement policy and payor behavior rather than on any one named customer, so coverage or rate changes would flow through to essentially the entire revenue base. Taken together, the two exposures are not diversifying; they reinforce one another. A single product sold through a reimbursement channel means the verdict hinges on continued coverage and payment for that one platform. Both exposures are clearly disclosed in the 10-K, and neither is offset by another business line.
For the engine’s reasoning on KMTS’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.
Industry peers · Medical Instruments & Supplies
Peer concentration profile
| Symbol | Name | HIGH | MEDIUM | LOW | Total |
|---|---|---|---|---|---|
| KMTS● | Kestra Medical Technologies, Lt | 2 | 0 | 0 | 2 |
| ATRC | AtriCure, Inc. | 1 | 1 | 1 | 3 |
| ATR | AptarGroup, Inc. | 1 | 1 | 0 | 2 |
| ALGN | Align Technology, Inc. | 1 | 0 | 0 | 1 |
| AVTR | Avantor, Inc. | 1 | 0 | 0 | 1 |
| ANGO | AngioDynamics, Inc. | 0 | 0 | 0 | 0 |
Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.